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ABSTRACT 
Prostratin exhibits potent HIV-1 latency reversing activity, yet its molecular mechanism of 
action has not been defined in detail. Here, we used a novel chemical biology approach which 
revealed that the protein kinase C-mitogen activated protein kinase kinase (PKC-Mel) pathway is 
essential for prostratin-induced reactivation of latent HIV-1 provirus. We identified 7 different 
Mek inhibitors using our approach that constantly impaired prostratin-induced reactivation. We 
also identified PKC inhibitors, Raf kinase inhibitors, and extracellular signal-regulated kinases 
(Erk) inhibitors that blocked prostratin-induced reversal of HIV-1 latency. Consistent with these 
observations, the PKC-Ras-Mek-Erk pathway plays an essential role in the mechanism by which 
prostratin reactivates latent HIV-1. In addition, we identified several kinase inhibitors that 
activated HIV-1 latent genes in a significant level individually, including CUDC-101, XMD8-92, 
PD173074, Quizartinib, and CUDC-907. Therefore, this chemical biology approach provides 
new methods of revealing the molecular mechanism of LRAs into the HIV-1 eradication 
research.  
The work represented by this thesis holds public health significances lying mainly in 
enriching the knowledge of HIV-1 latency reversing agents, contributing to the translational 
study, and the overall advancement of HIV eradication in public health.  
Nicolas Sluis-Cremer, PhD 
CHEMICAL-BIOLOGY APPROACH TO DELINEATE THE MECHANISM OF 
ACTION OF HIV-1 LATENCY REVERSING AGENTS 
Feng Han, MS 
University of Pittsburgh, 2017
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1.0  INTRODUCTION 
Since HIV-1 (human immunodeficiency virus type 1) was discovered 30 years ago as the 
causative agent of the acquired immunodeficiency syndrome (AIDS), the viral infection is 
always one of the major global health issues [1]. More than 75 million people worldwide have 
been infected with HIV-1, and there are approximately 36.7 million of people living with the 
infection [2]. Without the intervention treatments, the viral replication causes the loss of CD4+ T 
cells and a wide range of immunological dysfunction, increasing the risks of tumorigenesis and 
other accidental infections such as Kaposi's sarcoma-associated herpesvirus (KSHV) infection. 
The immunodeficiency caused by HIV-1 infection will lead to the further syndromes such as 
cardiovascular disease, bone diseases, and hepatic dysfunction. Antiretroviral drugs have been 
applied to the clinical treatment and intervention, which dramatically decreased the AIDS-related 
mortality rate since 2000. The continuous therapy can suppress viral replication and enable 
immune recovery, which also contributes to the epidemiological intervention. However, 
scientists are still seeking for a cure of HIV-1 to address this public health issue.  
1.1 HIV-1 LATENCY 
Viruses have evolved a variety of mechanisms to evade the host immune system. One of the 
mechanisms adapted by HIV-1 is the establishment of the latency in the infected cells. HIV-1 
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provirus can be expressed immediately in acute infections, followed by the viral replication cycle 
and the release of progeny viruses. Alternatively, depending on the status of the host cells, the 
provirus can become dormant. Once the latently infected cells encounter antigens or other 
activating stimuli, latency may be reversed, and the cells may begin to produce viruses[3]. 
The latency occurs when the provirus enters a non-productive, albeit reversible, state of 
replication. The HIV-1 proviral DNA integrates into cellular chromosomal DNA, existing in a 
permanent post-integration latent state. HIV-1 establishes latent infection mainly in resting 
memory CD4+ T cells with a long-life span[4]. The level of the viral gene transcription is very 
low, and little or no viral proteins are synthesized, which protects the infected cells from 
detection by the host immune system. There are several factors which contribute to the 
maintenance of latency, including the absence of nuclear forms of key host transcription factors 
(e.g. NFκB and NFAT) in resting CD4+ T cells, the absence of viral transactivator (e.g. Tat) [3], 
the presence of transcriptional suppressors such as CTIP2 (COUPTF Interacting Protein 2)[5], 
and the cellular microRNAs (miRNAs) which inhibits histone acetylation [6]. The regulated viral 
transcription in resting cells can be re-activated following exposure of appropriate stimuli, which 
was shown by numerous studies [7-9].  
1.2 TREATMENT OF HIV-1 INFECTION 
1.2.1 Antiretroviral therapy 
Currently, the most common way to treat HIV infection is through the use of a combination of 
targeted antiviral drugs, typically referred to as antiretroviral therapy (ART). ART is not a cure, 
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but it can control the viral load to reduce the AIDS-related death rate and transmission among a 
population. The approved antiretroviral drugs were classified into six categories, including 
nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, and HIV 
integrase inhibitors (Figure 1). The antiretroviral drugs are usually used in combinations of three 
or more drugs from more than one class as called “combination therapy” (cART) to prevent drug 
resistance.  
1.2.2 HIV eradication 
Two important features of HIV are its vast genetic diversity and its ability to rapidly evolve, 
which affect pathogenesis, prevention, diagnosis, and clinical treatment[10]. The vast diversity 
also implies the potential for rapid selection of drug resistance mutations during ART. In 
addition, new findings suggest that cells infected prior to initiating therapy can proliferate to very 
high numbers both before and during the ART[11], and a rebound in viremia can occur in 
patients after long-term cART[12]. Moreover, the pharmacokinetics properties of the drugs used 
to treat HIV-1 requires the delivery of  high doses to maintain the half-life of ARTs, which 
brings inconvenience to both clinicians and patients[13]. These studies highlight the need to find 
eradication methods. 
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Figure 1. The mechanism of antiretroviral therapy.  
The six drug classes include more than 25 HIV medicines that were approved by FDA to treat HIV infection. 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) are competitive analogues of deoxynucleotides that are 
necessary for the viral DNA chain synthesis. As the result, incorporation of NRTIs leads to the interruption of DNA 
synthesis due to the lack of 3’-hydroxyl group on the deoxyribose moiety. Non- Nucleoside Reverse Transcriptase 
Inhibitors (non-NRTIs) block reverse transcriptase by binding directly to the enzyme. Fusion inhibitors block the 
HIV envelope from merging with the host CD4+ T cell membrane. Protease inhibitors (PIs) block the viral protease 
activity that is crucial for the maturation of progeny viruses to become contagious. CCR5 antagonists block the HIV 
coreceptor to prevent HIV binding and fusion, and ultimately entry into cells. HIV integrase inhibitors block 
integration which is a vital step in retroviral replication.  
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1.3 BARRIERS TO HIV-1 ERADICATION 
1.3.1 Cellular HIV-1 Reservoirs 
During the HIV-1 infection, the activated CD4+ T cells are responsible for producing more 
progeny viruses, while the resting CD4+ T cells produce less or no viruses but are able to persist 
after ART[14]. There are two main populations of resting CD4+ T cells: naïve and memory CD4+ 
T cells, and infection occurs in both populations[15]. Memory T cells are the main reservoirs due 
to their long-life span and the regulation of cell division. The naïve CD4+ T cells also contribute 
to the latency reservoirs due to their ability to ability to proliferate and differentiate into any of 
the memory cell subsets[16].  
Due to the invulnerability of the resting CD4+ T cells reservoirs to antiretroviral drugs, 
cell-associated proviral DNA and RNA are still detectable in peripheral blood mononuclear cells 
(PBMC) by PCR-based assays, even after several years of cART [17], and therapy interruption 
leads to the re-emergence of viremia [18]. Moreover, one study showed that in individuals where 
cART might provide a period of control to the re-emergence of viremia after the interruption of 
therapy, the HIV-1 DNA predicted the time of plasma viruses rebound [19]. This suggests that 
the size of the reservoir indicates the period of time when viral rebound is controlled by cART 
after interruption of the treatment.  
1.3.2 The Shock and Kill Strategy 
A broadly proposed approach to reduce HIV-1 reservoir size involves reversing latency in 
patients on cART, as this would theoretically expose such cells to the killing by immune-
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mediated clearance, viral cytopathic effects, or other therapeutic strategies such as therapeutic 
vaccines (Figure 2). The early attempts of latency reversal were performed by using IL-2 and 
anti-CD3 monoclonal antibody (OKT3) combination [8, 20]. However, OKT3/IL-2 therapy 
resulted in global T cell activation and proliferation, which was toxic, and anti-OKT3 antibodies 
were rapidly induced[21]. Further research to find latency reversing agents (LRAs) that work 
without inducing T cell activation activity have led to the identification of individual compounds 
capable of reactivating HIV-1 latency. The identified LRAs can be categorized into the following 
groups based on their pharmacological targets: (1) histone deacetylase inhibitors (HDACi) such 
as Vorinostat; (2) cytokines and chemokines (e.g. IL-7); (3) DNA methyltransferase inhibitors 
(DNMTi); (4) protein C kinase (PKC) agonists such as Prostratin; (5) p-TEFb activators; (6) 
histone methyltransferase inhibitors (HMTi); and (7) unclassified agents such as disulfiram. 
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Figure 2 “Shock and Kill” strategy.  
The “shock and kill” strategy includes three steps: 1) LRAs are applied to the HIV reservoirs to activate the 
expression of latent genes. 2) Latent gene expression results in the production of viral proteins and progenies, which 
make them vulnerable to immune targeting and other treatment methods. 3) The combinatorial use of cART 
prevents the uninfected cells from new HIV infection.  
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1.4 THE DEVELOPMENT OF LATENCY REVERSING INTERVENTION 
1.4.1 Clinical Experiences with LRAs 
The clinical studies described that most of the identified LRAs were able to increase the HIV 
RNA production and/or the level of viremia when the single drug was applied alone in vivo, but 
the size of latent reservoirs was barely affected. Vorinostat, an HDACi approved by FDA for the 
treatment of cutaneous T-cell lymphoma[22], did increase the HIV-1 transcription in a 
significant level for two weeks, but this change remained at the same level when Vorinostat was 
given for 8 weeks[23]. Disulfiram, known as the acetaldehyde dehydrogenase inhibitor, was not 
able to reduce latent reservoirs at a significant level, despite the treatment increased the residual 
viremia in patients [24]. Moreover, the single use of LRAs that do not cause T cell activation is 
ineffective for the elimination of latency reservoirs[25]. On the other hand, studies focusing on a 
combinatorial use of LRAs suggested that the combination of proviral activators from different 
classes may have important implications for reducing the size of reservoirs[26]. Based on those 
observations, a combination of LRAs from two independent classes might be required for 
reservoir clearance. However, the combined effects of multiple LRAs involve with a complex 
mechanism which is not fully understood.  
1.4.2 PKC-θ agonist Prostratin functions as a LRA candidate 
Then PKC-θ was first isolated in the 1990s by Altman and his group[27] as a member of novel 
isoform (nPKCs) in Ca2+-independent PKC family. PKC-θ activates multiple transcriptional 
factors such NFκB and Activating protein-1 (AP-1), which are critical for the expression of 
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many T-cell activation-related genes such as IL-2[28]. Therefore, PKC-θ is regarded as one of 
important factors in the reactivation of HIV latent genes.  
Prostratin [13-O-acetyl-12-deoxyphorbol] is a phorbol ester that was first isolated from 
Strathmore weed Pimelea prostrate in 1976[29]. It showed the ability to prevent HIV-1 
infections by downregulating the HIV-1 cellular receptors CD4 and CXCR4 without any 
significant side effects[30]. Moreover, it was proved that prostratin can activate latent HIV viral 
reservoirs in vitro by stimulating IκB kinase (IKK)-dependent phosphorylation (through the 
stimulation of novel and atypical translocation protein PKC-θ) which leads to the translocation of 
NF-κB and NF-κB-dependent activation of HIV-1 LTR, while showing no effect to NFAT and 
AP-1[31]. Furthermore, unlike other phorbols which hyperactivate PKC and trigger cell 
proliferation leading to carcinogenesis, prostratin induces T-cell activation by upregulating 
surface marker CD25 and CD69 while inhibiting mitogen triggered T cell proliferation 
simultaneously[32].  
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2.0   STATEMENT OF THE PROJECT  
Previous studies have revealed that prostratin binds to PKC-θ and stimulates its kinase activity. 
Due to its unique pharmaceutical characteristics contributing to both HIV prevention and 
eradication, it is necessary to completely understand the mechanism in prostratin-induced latency 
reversal. Therefore, we designed a novel chemical biology approach to identify the cellular 
pathways that are involved with the maintenance and reversal of HIV latency, as well as the 
mechanism upon prostratin-induced latency reversal. Moreover, there is a possibility that this 
verified approach can be applied to delineate the mechanism of latency reversal induced by other 
drugs and identify the new potential LRAs. 
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3.0   SPECIFIC AIMS 
Aim 1: Establish a validated chemical biology approach that identifies potential LRAs by 
inhibiting crucial pathways involved with the maintenance of HIV latency. 
We orchestrated High-throughput screening by using different kinase inhibitor (From 
Kinase Inhibitor L-1200) individually to challenge HIV-1 latency model 24ST1NLESG cell line. 
Then we selected reagents with latency reversing ability according to the relative activity of seap 
(seap functions as an indicator of HIV late gene expression in the model). The selected reagents 
will be used in dose-response study to determine IC50 for the further studies  
 
Aim 2: Validated the approach by using prostratin to delineate the mechanism of prostratin-
induced reactivation. 
We used prostratin as the reference to verify the chemical biology approach on its ability 
to delineate the molecular events during the prostratin-induced latency reversal. By comparing 
the differences of inhibitor-treated cells with or without the presence of prostratin, we 
demonstrated that some inhibited pathways were essential in prostratin-induced reactivation, 
which was in consistency of previous studies. In the further step, we used dose-response assay 
and cell viability assay to eliminate the system error that affected internal validity.  
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4.0   MATERIALS AND METHODS 
4.1 CELL LINES AND MEDIA 
24ST1NLESG cell line (obtained from Joseph P. Dougherty’s Lab) was cultured in RPMI 1640 
L-glutamine (+) supplemented with 10% fetal bovine serum and 5% penicillin/streptomycin. 
Cells were cultured at a concentration of 2 × 106 cells/ml for all experiments. This human CD4+ 
T-cell clones were derived from the SupT1 cell inoculated with NLE-S-G vector. This pNL4-3-
based lentiviral vector contains all necessary cis-acting elements for HIV replication, and harbors 
both secreted alkaline phosphatase (seap) in the env position and enhanced green fluorescence 
protein (egfp) in the nef position (Figure 3). Moreover, the SEAP/GFP construct has a 2.5-kb 
deletion in pol and a 1.0-kb deletion in env to render the vectors replication-incompetent. 
Additionally, the vpu start codon in both constructs is mutated for robust marker gene 
expression.[33]. The seap gene encodes a truncated form of placental alkaline phosphatase, 
which catalyzes the alkaline phosphatase substrate CSPD [Disodium 3-(4-methoxyspiro {1,2-
dioxetane-3,2′ -(5′ -chloro)tricyclo [3.3.1.13,7]decan}-4-yl)phenyl phosphate] to generate 
chemiluminescent signals.   
Human SupT1 cell line (obtained from Dr. Zandrea Ambrose’s Lab) was cultured in 
RPMI 1640 L-glutamine (+) supplemented with 10% fetal bovine serum and 5% 
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penicillin/streptomycin. Cells were cultured at a concentration of 2 × 106 cells/ml for all 
experiments. 
 
Figure 3 The schematic diagram of HIV genes in NLE-S-G vector  
The vector contains two parts of deletion on pol and env gene for the safety purpose. It also contains egfp reporter 
gene in nef start codon, which serves as an early gene marker used in single cell analysis by flowcytometry. 
4.2 LATENCY-REVERSING AGENTS 
Prostratin was purchased from Sigma-Aldrich with a white powder form, which was further 
rehydrated in DMSO to a concentration of 50 mM, and diluted in DMSO to a working stock 
solution of 100 μM. Recombinant Human TNF-α was purchased from R&D System Inc with 
powder form, which was further reconstituted at 100 μg/mL in sterile PBS, and diluted to a 
working stock solution of 50 ng/mL. Romidepsin were purchased from Selleckchem and 
rehydrated in DMSO into a concentration of 5mM. The concentration of the working stock is 
500nM. All stocks and working solutions were stored at −20°C and used avoiding repeated 
freezing–thawing cycles. 
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4.3 LATENCY-REVERSING AGENT TREATMENT CONDITIONS. 
4.3.1 High-throughput screening 
24ST1NLESG cells were seeded into F-bottom 96 well cell culture plates at a concentration of 5 
× 105 cells/ml for all wells. Each well contains 100 µl of cell culture. Cells were stimulated with 
kinase inhibitors or latency-reversing agents at the following concentrations for all single and 
combination treatments unless otherwise indicated: 20 µM kinase inhibitor as screening 
concentration, 1 µM prostratin, 50 ng/ml TNF-α, or media alone plus DMSO. The final DMSO 
percentage was 1% (v/v) for all single and 2% (v/v) for all combinatorial treatments. 
Concentrations and incubation time were chosen based on the previous time course and dose-
response studies in vitro with 24ST1NLESG cells as well as. 
4.3.2 Drug dose-responses assays 
To determine drug IC50, 24ST1NLESG cells were seeded in F-bottom 96 well cell culture plates 
at a density of 50,000 cells per well in a volume of 98 μl. 1 μl of prostratin was added into each 
well with a final concentration of 1µM. 1 μl of selected inhibitors (diluted to working stocks with 
following concentrations: 2 mM, 500 μM, 125 μM, 31.25 μM, 7.8 μM, and 1.95 μM) were added 
into each well in combination with prostratin. A DMSO control and a prostratin control were 
used on each plate. The final DMSO percentage was 2% (v/v) for all the treatments. All results 
were normalized to the average DMSO control for individual wells. IC50 values were calculated 
by plotting luminescence counts per second (LCPS) against the drug concentration and fitting a 
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nonlinear regression curve using GraphPad Prism vision 6 and SigmaPlot version 11.0 for 
Windows.  
4.4 MEASUREMENT OF SEAP CHEMILUMINESCENCE 
After treatment, the cell cultures were heated at 65 °C for 30 minutes to inactivate endogenous 
alkaline phosphatase, while the SEAP was stable under this condition. The cell SEAP gene 
expression was assayed using alkaline phosphatase substrate CSPD with Sapphire-II™ Enhancer 
(purchased from ThermoFisher). The CSPD and cell culture were mixed in a white opaque 96-
well plate. Each well contains 50 μl CSPD and 10 μl cell culture (heat inactivated). Then the 
plate was set in 1450 MicroBeta TriLux machine to incubate 15 minutes and read the 
chemiluminescence.  
4.5 CELL VIABILITY ASSAY 
The CellTiter-Glo® Luminescent Cell Viability Assay (Purchased from Promega Corporation) 
was used to estimate the biological viability of the SupT1 cells. This assay determines the 
number of viable cells in culture based on quantitation of ATP, which indicates the presence of 
metabolically active cells. SupT1 cells was placed in the opaque 96-well plate at a density of 
50,000 cells per well in a volume of 98 μl. The cells were incubated with/without reagents that 
was used in dose-response study for 48 h at 37 °C. The 100 μl assay reagent was added into each 
16 
well. After 10 minutes of incubation, the 96-well plate was analyzed using an luminescence 
reader 1450 MicroBeta TriLux machine. 
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5.0   RESULTS 
5.1 24ST24ST1NLESG CELLS SERVES AS HIV-1 LATENCY MODEL 
For the assay to be reliable in an HTS in a small-well format, the HIV-1 latency model 
24ST24ST1NLESG cells were stimulated with TNF-α to test the latent gene expression. The 
results showed that seap, the indicator of late gene expression, were detected from the cell 
culture, and the level of expression was increasing following the time courses (Figure 4A). This 
verified the reliability of the model as previously described [33]. Then we designed a dose-
response study to determine the best concentration of prostratin to use in this model. The result 
showed that prostratin induced the peak level of seap expression at the concentration of 1 µM 
(Figure 4B). Based on these studies, we designed a time course study to determine the optimal 
incubation time for prostratin-induced latency reversal. After 48 hours of incubation, the level of 
seap expression in cells treated with prostratin was more than 3 times higher than that in cells 
treated with DMSO (Figure 4C).  
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A                                                                                    B 
C           
 
Figure 4. Time course and dose-response studies.  
3A. 24ST24ST1NLESG cells (106/ml) were exposed to TNF-α (50ng/ml). The expression of seap gene was 
measured at different time points. The negative vehicle control was sterile PBS containing 0.1%FBS (due to the 
reason that TNF-α was added 0.1% FBS to maintain stability). 3B. 24ST24ST1NLESG cells (106/ml) were exposed 
to TNF-α (50ng/ml), different concentration of prostratin, and DMSO. Seap expression was measured after 48 hours 
of incubation. 3C. 24ST24ST1NLESG cells (106/ml) were exposed to 1µM prostratin, 5 nM Romidepsin, and 
DMSO. Romidepsin and DMSO served as positive and negative controls. Seap expression was measured after 
different incubation time periods. Results shown are the means and standard deviations of three representative 
experiments.  
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5.2 SCREENING AGENTS THAT CAN REACTIVATE HIV-1 LATENCY 
To identify the cellular pathways that are involved with latency reversal, we conducted a high-
throughput screening using Kinase Inhibitor Library L-1200 (418 inhibitors) targeting kinases 
such as receptor tyrosine kinases (RTKs), phosphoinositide 3-kinase (PI3K), Aurora Kinase, 
Cyclin-dependent kinases (CDK), extracellular signal–regulated kinase (Erk), and Mitogen-
activated protein kinase kinase (MEK). DMSO and prostratin were used as the negative and 
positive control.  
For each well that was treated with single kinase inhibitor alone, the LCPS was 
normalized with LCPS in the DMSO-treated group. We selected the reagents with L̅ (the average 
of normalized LCPS values) larger than 3 as the potential drugs with latency reversing ability. 
The screening was repeated 6 times under same conditions. The results showed that most of the 
inhibitors reversed latent genes by targeting HDAC, JAK/STAT pathway, and different types of 
growth factor receptors (Table 1). CUDC-101 and XMD8-92 showed the reproducible results of 
reversing HIV-1 latent genes in every screening.  
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Table 1. Pathways that are involved with HIV-1 latency reversal in 24ST24ST1NLESG cells model. 
Frequency Target Drug L ̅ SD 
6/6 EGFR,HER2,HDAC CUDC-101 5.4427 1.7907 
ERK, Brd4 XMD8-92 3.8233 0.2696 
5/6 VEGFR,FGFR PD173074 6.3228 1.5877 FLT3 Quizartinib 4.9727 1.6423 
PI3K,HDAC CUDC-907 5.0932 2.3393 
4/6 
Bcr-Abl Nilotinib 5.4289 2.4202 
PDGFR,c-Kit Masitinib 6.2045 3.0210 
CDK Palbociclib-HCl 94.7300 34.4822 
PI3K TGX-221 5.0351 1.3368 
PDGFR Imatinib 12.2218 7.6163 
DNA-PK,PI3K NU7441 4.1203 1.0548 
JAK CEP-33779 13.3691 4.5881 
JAK Filgotinib 3.4344 0.5282 
3/6 ATM/ATR KU-55933 3.1717 0.0976 PLK Ro3280 7.4889 5.6895 
AMPK HTH-01-015 7.1006 1.4822 
5.3 IDENTIFIED CELLULAR PATHWAYS AFFECTING PROSTRATIN-INDUCED 
LATENCY REVERSAL BY USING HTS 
To identify the potential cellular pathways which are involved with prostratin-induced latency 
reversal, we used the same L-1200 library screening in combination with prostratin. DMSO and 
prostratin alone were used as negative and positive controls.  
For each well, an R-value was given to function as the parameter. R value for the 
screening was calculated based on the analysis of SEAP expression from one single treatment 
(one kinase inhibitor alone) and one combinatorial treatment (same kinase inhibitor plus 
prostratin) using the equation:  
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with L representing the luminescence counts per second (LCPS), while KI and P represent 
treatment with kinase inhibitor and/or prostratin. We used R ≤ 0.36 as the cut-off value to select 
reagents that inhibit the prostratin-induced latency reversing. To eliminate false positive results 
due to cytotoxicity, the drugs were excluded if the denominator ( DMSOKI LL ÷ ) of R value was 
less than 0.4. The screening was repeated three times under same conditions.  
The screening results showed that Palbociclib, Nilotinib (Bcr-Abl inhibitor), HTH-01-
015 (AMPK inhibitor), and 7 Mek inhibitors are reproducible among all three repeats (Table 2). 
This result implied that Mek inhibitors negatively affect prostratin-induced latency reversal. The 
Palbociclib and Nilotinib were showed in the former screening with the ability to reverse latency 
in a significant level (Table 1). However, the combinatorial use of them with prostratin showed 
the opposite effect reproducibly.  
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Table 2. Summary of reagents that inhibit prostratin-induced latency reversing.  
Frequency Target Drug R� SD 
3/3 MEK Selumetinib  0.1327 0.0713 
MEK U0126-EtOH 0.2031 0.1409 
MEK PD0325901 0.1620 0.0935 
MEK Refametinib 0.1664 0.0942 
MEK Trametinib 0.1776 0.1072 
MEK TAK-733 0.2006 0.1122 
MEK MEK162 0.0945 0.0451 
CDK Palbociclib-HCl 0.1287 0.0772 
Bcr-Abl Nilotinib  0.2289 0.0531 
AMPK HTH-01-015 0.2203 0.0649 
2/3 MEK Pimasertib   0.1588 0.1466 
MEK PD318088 0.1457 0.1373 
MEK AZD8330 0.0493 0.0109 
Raf GDC-0879 0.2472 0.1157 
Raf Dabrafenib 0.2731 0.0291 
ERK Ulixertinib 0.1926 0.1490 
PKC Sotrastaurin 0.1404 0.0254 
JAK LY2784544 0.3071 0.0031 
JAK CEP-33779 0.0902 0.0643 
JAK Filgotinib 0.1446 0.0543 
PI3K TGX-221, 0.1690 0.0577 
PI3K, HDAC CUDC-907 0.1839 0.0332 
Aurora Kinase AMG-900 0.2264 0.1462 
EGFR,HER2,HDAC CUDC-101 0.1161 0.0251 
FLT3 Quizartinib 0.3496 0.0019 
JAK,EGFR AG-490 0.158 0.0990 
LRRK2 GNE-7915 0.1815 0.2195 
PAK FRAX597 0.2213 0.0224 
PDGFR,c-Kit Masitinib 0.2238 0.0884 
PLK Ro3280 0.1623 0.1241 
Syk Piceatannol 0.3096 0.0549 
 
23 
5.4 PROSTRATIN-INDUCED REACTIVATION IS SINSITIVE TO MEK 
INHIBITORS 
To verify the screening results, 24ST1NLESG cells were cultured in 96 well plates at a density 
of 50,000 per well. Prostratin was used at concentrations previously shown to be effective in 
reversing latency in the model system. The kinase inhibitors were applied at the beginning 
concentration of 20 µM. The concentration was diluted to one-fourth with DMSO, and the 
concentration of DMSO remains same among all the wells. In the Mek inhibitors dose-response 
tests, all of the Mek inhibitors exhibited a dose-response, showing increased inhibition at 
increased doses. (Figure 5 A). However, U0126-EtOH showed a lower level of inhibition activity 
to prostratin-induced reactivation even at a high concentration (Figure 5 A). On the contrary, 
CDK inhibitor Palbociclib-HCl and AMPK inhibitor HTH-01-015 didn’t show an obvious dose-
response curve to the inhibition effect (Figure 5 E). 
5.5 PROSTRATIN INDUCED LATENCY REVERSAL THROUGH PKC-MEK-ERK 
PATHWAY 
To determine the pathway which prostratin induced in the latency reactivation, we further did 
dose-response study using inhibitors that target different kinases specifically in PKC-Mek 
pathway including PKC, Raf, and Erk. The inhibitors were applied at the beginning 
concentration of 20 µM and then diluted to one-fourth with DMSO as same as that was in Mek 
inhibitors dose-responses study. The results showed dose-response curves on both PKC and Erk 
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inhibitors (Figure 5B and C). The inhibitory activity of Raf inhibitors dropped slowly following 
the increasing doses (Figure 5D).  
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Figure 5. Drug dose-responses study and IC50 determination.  
4A and 4E. The cells were treated with different Mek inhibitors, HTH-01-015, or Palbociclib at the diluted 
concentrations (20 µM, 5 µM, 1.25 µM, 312.5 nM, 78.13 nM, and 19.53 nM) individually, combined with 1 µM 
prostratin for 48 hours of incubation. The data was normalized with cells treated with 2% DMSO (v/v). 4B, 4C, and 
4D. Cells were treated with Sotrastaurin, Ulixertinib, or selected Raf inhibitors at the different concentrations (20 
µM, 5 µM, 1.25 µM, 312.5 nM, 78.13 nM, and 19.53 nM) individually, combined with 1 µM prostratin for 48 hours 
of incubation. Results shown are the means and standard deviations of three representative experiments. The IC50 
was calculated with SigmaPlot. 
5.6 CELL VIABILITY ASSAY 
As the screening and dose-response assay showed earlier, Prostratin-induced reactivation was 
inhibited by several reagents including 7 Mek inhibitors (Selumetinib, U0126-EtOH, 
PD0325901, Refametinib, Trametinib, TAK-733, and MEK162), two Raf inhibitors (GDC-0879 
and Dabrafenib), Erk inhibitor (Ulixertinib), and PKC inhibitor (Sotrastaurin). Our next step was 
to determine if the reduction of prostratin-induced reactivation was caused by cytotoxicity. For 
this purpose, we carried out the cell viability assay with or without the challenge of kinase 
inhibitors, and in both cases, we measure the relative viability using PBS-treated cells as the 
reference. We observed that the stimulation with Mek inhibitors, especially Trametinib, 
significantly reduced the viability at the concentration of 20 µM compared with PBS-treated 
cells (Figure 6 A). The Ulixertinib and Sotrastaurin led to the decrease of viability around 50% 
with the high-dose treatment (Figure 6 B and C). However, GDC-0879 and Dabrafenib were able 
to maintain the viability over 90% above even at high-dose treatment (Figure 6 D). Moreover, 
we also tested Palbociclib-HCl and HTH-01-015 to verify the latency reversing ability showed in 
the Screening (Table 1). The results showed that the viability remained steady following the 
increasing doses, but dramatically reduced at the high-dose treatment (20 µM) (Figure 6 E).  
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Figure 6. Cell viability assay using PKC, Raf, Mek, Erk, AMPK, and CDK inhibitors 
5A. Cell viability test for prostratin-treated SupT1 cells under the stimulation of Mek inhibitors. 5B and 5C. Cells 
were grown in the presence of prostratin and PKC or Erk inhibitor for 48 hours and were used to measure the final 
cell viability. Responses were normalized using PBS-treated cells as reference. The relative viability at the highest 
dose (dose of 20 µM, used in previous screenings) was showed in the figures.  
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6.0   DISCUSSION  
6.1 CELL LINE MODEL 
In this study, 24ST24ST1NLESG cell line was applied to mimic the HIV-1 infected resting 
CD4+ T-cells in patients. The cell clones were derived from human SupT1 cells, latently infected 
with an HIV-1NL4-3-based reporter construct SEAP/GFP. As the report, genes carried on this 
vector can be induced by TNF-α[34]. This cell model was also used by Dougherty’s group in the 
study of SAHA for treating T-cell lymphoma research[35] and Cochrane’s group in Digoxin-
suppressed HIV-1 replication study[36]. Our study also suggests the consistency and reliability 
of the replication-competent HIV-1 model in drug-induced reactivation. Moreover, our study 
shows that Prostratin induces a higher level of latency reversal compared with Romidepsin in the 
cell line model, which was in consistency with the study from Siliciano’s group who used resting 
CD4+ T-cells from infected individuals on suppressive ART[37]. This suggests that 
24ST24ST1NLESG cell line is capable of representing latently infected resting CD4+ T-cells in 
HIV-infected patients.  
The cell line was derived from SupT1 cells which are T lymphoblast cells expressing 
CD4 and CD45RO on the surface (showed on CD45RO Antibody (UCH-L1) from Santa Cruz 
Biotechnology). This indicates that 24ST1NLESG cells are similar to resting memory CD4+ T-
cells. It is established that Resting memory CD4+ T-cells represent main reservoirs, however, 
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additional reservoirs could further complicate eradication efforts. Evidence for additional 
reservoirs was showed from a detailed analysis of residual viremia. The study from Toronto 
Mucosal Immunology Group and the University of Toronto suggests some latently infected 
reservoirs (especially TH1 and TH17 reservoirs) were established under the regulation of 
immunosuppressive cytokines such as interleukin (IL)-10 and transforming growth factor-beta 
(TGF-β) which inhibit CD4+ T-cells activation[38]. In addition, macrophages are regarded as 
potential reservoirs due to their higher resistance to viral cytopathic effects than activated CD4+ 
T-cells[39]. Furthermore, the high expression of P-glycoprotein transporter in macrophages has 
been reported to limit the availability of ART drugs[40]. Therefore, macrophages could serve as 
reservoirs if they can persist in an infected state during the years of ART. To increase the internal 
validity of this study, the other cell models should be applied to this chemical biology approach 
such as Bosque/Planelles’ model using naïve CD4+ T-cells that were activated by anti-CD3 and 
anti-CD28 in vitro and infected with an NL4-3-based virus. Moreover, PBMCs isolated from 
HIV-1-infected patients under the ART should be used in the further study to verify the results. 
6.2 THE IDENTIFIED LRAS BY SCREENING 
The chemical biology approach in this study identified several kinases that are involved with the 
reversal of HIV latency, including Erk, HDAC, EGFR/FGFR, PI3K, and JAK. Five agents were 
identified to reverse HIV-1 latency reproducibly, including CUDC-101, XMD8-92, PD173074, 
Quizartinib, and CUDC-907. Inhibition of HDAC was showed in the earlier study that induced 
the latency reversing both in vitro and in vivo[41]. CUDC-101 and CUDC-907 inhibit 
HDAC[42, 43] which may reverse the latency as same as other HDACi LRAs. XMD8-92 is an 
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Erk 5 and Brd4 specific inhibitor, which was used to regulate TCR/CD3 expression in Xavier 
Rovira-Clavé’s study[44]. Erk 5 is the last MAP kinase family member which involves in 
MEK5-ERK5 pathway linked to different cellular processes, playing a crucial role in cell 
proliferation in normal and cancer cells[45]. However, recent studies show that the anticancer 
activity of Erk 5 should be carefully interpreted. It has been reported that several kinase 
inhibitors can strongly inhibit the bromodomain-containing protein-4 (Brd4), a general 
transcription co-activator[46]. XMD8-92 shows similar potency in which its antitumor effects 
could be compromised by the Brd4-inhibiting activity[47]. Compared what we found in this 
study, the XMD8-92 shows the ability to activate latent gene rather than inhibits latent gene 
activation by deactivating Erk and Brd4. This suggests that the further study of XMD8-92 using 
PBMCs isolated from HIV-infected patients is required. Quizartinib is used on a clinical trial for 
the treatment of Acute myeloid leukemia (AML)[48]. It has been reported that the presence of 
FMS-like tyrosine kinase-3 (FLT3) was highly associated with the signal transducers and 
activators of transcription 5 (STAT5)[49]. Therefore, one explanation is that Quizartinib 
suppressed FLT3 activity leading to the inhibition of JAK/STAT pathway, which is in 
consistency with other JAK inhibitors (such as CEP-33779 and Filgotinib) inducing latency 
reactivation (Table 1). Above all, our next step should focus on the verification of the theory by 
using FLT3-siRNA or Brd4-siRNA and the application of those reagents in PBMCs. Per se, 
future studies of these speculative matters may bring new concepts to what is known so far. 
This approach is based on 24ST24ST1NLESG cell line, which introduces biological 
variance due to the variability in individual cell responding to the pharmaceutical stimuli. 
Moreover, the screening was processed using a multichannel pipette, which brings the random 
error to this system. It is showed that the standard deviation of Palbociclib-HCl is 34.4822 (Table 
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1), which is infeasible to be fixed by increasing the internal validity. To increase the external 
validity by minimizing the random error caused by multichannel pipette, a large number of 
replicants should be used in this study. However, this may bring another obstacle into the 
procedure, i.e. a large number of experimental replications requires a high-volume workload 
operated by individuals.  
6.3 VARIFICATION OF THE BIOLOGY APPROACH USING PROSTRATIN 
Three agents, Palbociclib-HCl, Nilotinib, and HTH-01-015 showed activity to reverse the latency 
alone three or more times among 6 parallel repeat experiments. Among these three agents, 
Palbociclib and HTH-01-015 were reported only for their ability to suppress tumor cell 
proliferation[50, 51], while their ability to reactivate HIV-1 latency remains unknown. However, 
when those agents were used in combination with prostratin, the reversal of latency was 
significantly inhibited. The cell viability assay result suggests that the combinatorial use of 
prostratin with Palbociclib or Nilotinib leads to the significant reduction of cell viability (Figure 
6 E). One explanation of the screening results (showed in Table 2) is that the combination is 
highly cytotoxic to the cell line, which affected the numerator and lowered the R value. Further 
studies are required to elucidate the mechanism of the cytotoxicity from the combination of those 
drugs.  
This approach also revealed that several kinases are critical in prostratin-induced latency 
reversal, including Mek, Erk, Raf, and PKC. The following dose-response assays suggest that 
prostratin may activate the signaling cascade through PKC-Raf-Mek-Erk to induce the 
expression of proviral latent genes. Xiaoyu Yang’s study showed similar results that Erk 
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activated latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-κB[52]. 
Egbert Flory’s study showed that Raf agonists activated NF-κB and HIV-1 replication in T 
cells[53]. In summary, these earlier studies suggest that activation of Raf/Mek/Erk pathway 
upregulates HIV replication and infectivity, and PKC and Erk activation induce the reactivation 
of HIV-1 latency. Based on the results from this study, we conclude that Mek is activated in 
prostratin-induced HIV-1 latency reversal, which stimulates NF-κB-dependent transcription 
activation through PKC/Raf/Mek/Erk signaling cascade. Additional assays such as phosphor-
specific Western Blot analysis and RNAi will be required in future studies to verify the signaling 
cascade and the functions of kinases.  
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7.0  PUBLIC HEALTH SIGNIFICANCE 
The proposed research is relevant to the public health because the HIV-1 infection is still one of 
the major global costs measured by both patient suffering and economic burden. Despite 
effective treatment, HIV-infected individuals have a higher risk of heart diseases, kidney 
dysfunction, and neurological disease. In 2015, an estimated 36.7 million people were living 
with HIV, including 1.8 million children[54]. Among these people, 18.2 million people were 
accessing ART. However, the prevalence of HIV infection is higher among developing countries 
and poverty-stricken areas such as Angola, Kenya, Zimbabwe, Indonesia, and Brazil[55]. Among 
all the infected individuals, males accounted for 81% of all diagnoses of HIV infection, which 
indicates that HIV transmission remains common in many vulnerable populations, including men 
who have sex with men and injection drug users. As of December 2015, 46% of all adults and 
49% of all children living with HIV were accessing to ART[54]. On the other hand, clinical 
studies focusing on HIV eradication showed that candidate LRAs including HDACi (Vorinostat, 
panobinostat, romidepsin), disulfiram, and JQ1 (bromo and extra terminal bromodomain 
inhibitor) only activated HIV-1 latency in a small subtype of resting CD4+ T cells[25]. 
Moreover, some combinatorial uses of LRAs from different classes showed an outstanding effect 
on latency reactivation ex vivo[37], yet the mechanism of this remains unclear. Therefore, by 
using this chemical biology approach, the action on LRA-induced latency reversal will be 
35 
delineated to provide a better understanding of the mechanism. Thus, it contributes to the overall 
advancement of HIV eradication in public health.  
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